J. Goldman & Co LP Buys Shares of 242,787 Merit Medical Systems, Inc. $MMSI

J. Goldman & Co LP bought a new stake in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 242,787 shares of the medical instruments supplier’s stock, valued at approximately $16,835,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. State Street Corp raised its stake in Merit Medical Systems by 1.5% during the fourth quarter. State Street Corp now owns 2,231,048 shares of the medical instruments supplier’s stock valued at $196,645,000 after buying an additional 32,459 shares during the last quarter. Conestoga Capital Advisors LLC increased its holdings in shares of Merit Medical Systems by 3.9% during the first quarter. Conestoga Capital Advisors LLC now owns 2,167,513 shares of the medical instruments supplier’s stock valued at $149,407,000 after acquiring an additional 81,030 shares in the last quarter. Fuller & Thaler Asset Management Inc. raised its position in shares of Merit Medical Systems by 12.7% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock worth $183,137,000 after purchasing an additional 234,682 shares during the last quarter. Wellington Management Group LLP boosted its stake in Merit Medical Systems by 7.0% in the 4th quarter. Wellington Management Group LLP now owns 1,327,013 shares of the medical instruments supplier’s stock worth $116,963,000 after purchasing an additional 86,504 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Merit Medical Systems by 1.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,237,298 shares of the medical instruments supplier’s stock valued at $85,287,000 after purchasing an additional 12,285 shares in the last quarter. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on MMSI. Robert W. Baird set a $98.00 price target on shares of Merit Medical Systems in a report on Friday, July 31st. Piper Sandler upped their price objective on Merit Medical Systems from $96.00 to $106.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Needham & Company LLC lifted their target price on Merit Medical Systems from $90.00 to $101.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Canaccord Genuity Group boosted their price target on Merit Medical Systems from $85.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Bank of America increased their price objective on Merit Medical Systems from $92.00 to $97.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Eight equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $100.00.

More Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Broad upward revisions to earnings forecasts: Zacks Research increased its FY2026 EPS estimate to $3.73 from $3.57, FY2027 to $4.01 from $3.82, and FY2028 to $4.32 from $4.12. Estimates were also raised for Q2 2027, Q3 2027, Q1 2028 and Q2 2028, suggesting improving expectations for Merit Medical’s earnings trajectory.
• Positive Sentiment: Growth initiatives are strengthening the investment case: New product launches, acquisitions and a broader portfolio of therapeutic medical products are supporting stronger growth and improving the company’s business mix. Recent quarterly results also showed revenue growth and an EPS beat, while the company raised its 2026 outlook. Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
• Neutral Sentiment: Short-interest data provides no meaningful signal: Reported short interest was zero shares both on August 10 and August 25, with a zero-day days-to-cover ratio. The reported “increase” is mathematically invalid, so the data does not indicate either meaningful short covering or rising bearish positioning.
• Negative Sentiment: Valuation and risk remain concerns: MMSI’s recent rally has left the stock trading at a premium valuation, increasing the need for continued earnings delivery. Analysts also cited tariff exposure and execution risks related to launches and acquisitions as potential headwinds. Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?

Merit Medical Systems Trading Up 0.9%

Shares of MMSI stock opened at $91.09 on Wednesday. The company has a current ratio of 4.20, a quick ratio of 2.79 and a debt-to-equity ratio of 0.44. Merit Medical Systems, Inc. has a 12-month low of $59.74 and a 12-month high of $94.75. The stock has a market capitalization of $5.44 billion, a P/E ratio of 37.64, a P/E/G ratio of 2.25 and a beta of 0.49. The firm’s 50 day moving average is $78.35 and its 200 day moving average is $72.66.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.23. The firm had revenue of $418.84 million for the quarter, compared to analysts’ expectations of $405.25 million. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%.The company’s revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.01 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. Research analysts expect that Merit Medical Systems, Inc. will post 3.84 earnings per share for the current year.

Merit Medical Systems Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.